Neuralink says it will move to high-volume production of its brain implant in 2026, and this piece walks through what the device does, how it works, its regulatory path, and early human uses, including a paralyzed patient now typing with thought alone.
Neuralink’s implant aims to bridge brain and computer by reading electrical signals produced by neurons and turning those signals into digital commands. The company touts a compact device that sits under the skull to detect and interpret neuronal activity, enabling users to control tools without physical movement.
Electrodes are placed near neurons to pick up “action potentials,” the tiny electrical spikes neurons send when they fire. Those signals are then analyzed to decode patterns tied to intended movements, sensations, or thoughts, which lets the implant translate brain activity into actionable outputs.
“In the movement-related areas of the brain, for example, neurons represent intended movements. There are neurons in the brain that carry information about everything we see, feel, touch or think,” the company explains, highlighting the breadth of signals the system is trying to capture. Decoding those patterns is the technical heart of the device and what makes direct brain control possible.
The physical chip is described as fully implantable and cosmetically invisible, measuring just 1.75 inches thick, designed to sit flush beneath the scalp. That compact profile is meant to reduce obvious signs of the device while housing electrodes, processing units, and wireless communication capability.
The path to human use was not immediate. Neuralink’s initial application for trials was rejected in 2022, and the company spent time addressing safety and procedural concerns raised by regulators. After adjustments and additional data, human testing began in 2024 under tighter oversight and with renewed focus on participant safety.
One early recipient, a man with advanced ALS named Brad Smith, became the third person to receive a Neuralink implant and demonstrated the system by using it to type. Smith, who is completely paralyzed and relies on a ventilator, shared a video showing the brain-computer interface controlling the mouse on his MacBook Pro.
Smith posted about his experience and wrote, “I am typing this with my brain. It is my primary communication,” and he expressed gratitude toward the team involved. His ability to transform thought into text in real time is a concrete example of the technology’s intended utility for people with severe motor loss.
Beyond individual stories, the company reported that as of September a dozen people with severe paralysis worldwide had received Neuralink implants. Those participants are using the devices to operate digital interfaces and physical tools, showing a range of potential applications from communication aids to environmental control.
Scaling from a handful of trial implants to “high-volume” manufacturing in 2026 will require expanding supply chains, surgical training, and device validation at a much larger scale than the early trials. Production plans aim to make the hardware available to more patients, but mass rollout also raises questions about distribution, long-term support, and follow-up care for implanted users.
Regulators and medical teams are closely watching outcomes as real-world data accumulates from trial participants. The company’s earlier regulatory hurdles underscore that safety, surgical protocol, and device reliability remain central concerns before broader clinical adoption.
For now, Neuralink’s announcements and the early patient experiences offer a glimpse of how brain-computer interfaces could restore communication and control to people who have lost motor function. The coming production push will test whether the technology can move from experimental implants into wider clinical use while maintaining thorough safety standards.
Neuralink did not immediately respond to a request for comment.
